University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Dolores Shoback

Dolores Shoback, M.D.

Endocrinologist

Dr. Dolores Shoback sees general endocrine patients with an emphasis on metabolic bone disease, parathyroid disorders and osteoporosis. She is board certified in internal medicine with a subspecialty in endocrinology and metabolism. A professor of medicine and director of the UCSF Training Program in Diabetes, Endocrinology and Metabolism, her research interests are metabolic bone disease, the calcium sensing receptor and parathyroid hormone. Shoback completed her undergraduate studies at the University of Pennsylvania. She went on to Johns Hopkins University for medical school and performed a residency in internal medicine at Johns Hopkins Hospital and then completed a fellowship in endocrinology at Brigham and Woman's Hospital in Boston.

Clinics

Endocrinology Clinic at Parnassus
400 Parnassus Ave., Suite A-550
San Francisco, CA 94143
Phone: (415) 353–2350
Fax: (415) 353–2337

Hours: Monday to Friday, 8:30 a.m. – 5 pm.

Conditions & Treatments

More about Dolores Shoback

Education

Johns Hopkins School of Medicine 1977

Residencies

Johns Hopkins Hospital, Internal Medicine 1980

Fellowships

Brigham and Woman's Hospital, Endocrinology 1983

Selected Research and Publications

  1. Cheng Z, Liang N, Chen TH, Li A, Santa Maria C, You M, Ho H, Song F, Bikle D, Tu C, Shoback D, Chang W. Sex and age modify biochemical and skeletal manifestations of chronic hyperparathyroidism by altering target organ responses to Ca(2+) and parathyroid hormone in mice. J Bone Miner Res. 2013 May; 28(5):1087-100.
  2. Park-Sigal J, Don BR, Porzig A, Recker R, Griswold V, Sebastian A, Duh QY, Portale AA, Shoback D, Schambelan M. Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone. J Bone Miner Res. 2013 Mar; 28(3):700-8.
  3. Schafer AL, Sellmeyer DE, Palermo L, Hietpas J, Eastell R, Shoback DM, Black DM. Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab. 2012 Oct; 97(10):3522-9.
  4. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012 Jul; 97(7):2272-82.
  5. Dvorak-Ewell MM, Chen TH, Liang N, Garvey C, Liu B, Tu C, Chang W, Bikle DD, Shoback DM. Osteoblast extracellular Ca2+ -sensing receptor regulates bone development, mineralization, and turnover. J Bone Miner Res. 2011 Dec; 26(12):2935-47.
  6. Prasad AP, George V, Porzig A, Horvai AE, Gross A, Shoback D, Link TM. Progressive craniofacial bone loss after cosmetic surgery at the forehead. Skeletal Radiol. 2012 Apr; 41(4):477-81.
  7. Schafer AL, Sellmeyer DE, Schwartz AV, Rosen CJ, Vittinghoff E, Palermo L, Bilezikian JP, Shoback DM, Black DM. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab. 2011 Dec; 96(12):E1982-9.
  8. Bilezikian JP, Khan A, Potts JT, Brandi ML, Clarke BL, Shoback D, Jüppner H, D'Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders J. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011 Oct; 26(10):2317-37.
  9. Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab. 2011 Jan; 96(1):E9-18.
  10. Dong Q, Cheng Z, Chang W, Blackman BE, Conte FA, Hu J, Shoback D, Miller WL. Naturally-occurring mutation in the calcium-sensing receptor reveals the significance of extracellular domain loop III region for class C G-protein-coupled receptor function. J Clin Endocrinol Metab. 2010 Oct; 95(10):E245-52.
  11. Chang W, Dvorak M, Shoback D. Assessing constitutive activity of extracellular calcium-sensing receptors in vitro and in bone. Methods Enzymol. 2010; 484:253-66.
  12. Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab. 2009 Dec; 94(12):4860-7.
  13. Pao VY, Chang S, Shoback DM, Bikle DD. Hypercalcemia and overexpression of CYP27B1 in a patient with nephrogenic systemic fibrosis: clinical vignette and literature review. J Bone Miner Res. 2009 Jun; 24(6):1135-9.
  14. Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009 Aug; 94(8):2766-72.
  15. Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009 Feb; 94(2):373-81.
  16. Chang W, Tu C, Chen TH, Bikle D, Shoback D. The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Sci Signal. 2008; 1(35):ra1.
  17. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008 Jul 24; 359(4):391-403.
  18. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab. 2007 Oct; 92(10):3803-8.
  19. Cheng Z, Tu C, Rodriguez L, Chen TH, Dvorak MM, Margeta M, Gassmann M, Bettler B, Shoback D, Chang W. Type B gamma-aminobutyric acid receptors modulate the function of the extracellular Ca2+-sensing receptor and cell differentiation in murine growth plate chondrocytes. Endocrinology. 2007 Oct; 148(10):4984-92.
  20. Chang W, Tu C, Cheng Z, Rodriguez L, Chen TH, Gassmann M, Bettler B, Margeta M, Jan LY, Shoback D. Complex formation with the Type B gamma-aminobutyric acid receptor affects the expression and signal transduction of the extracellular calcium-sensing receptor. Studies with HEK-293 cells and neurons. J Biol Chem. 2007 Aug 24; 282(34):25030-40.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California